Description of various polymers/hydrogel systems utilized for the treatment of skin cancer
| No. | Polymers (hydrogels) | Cell/cell lines | Type of cancer | Results | References |
|---|---|---|---|---|---|
| 1. | Chitosan hydrogel | A mouse model of CD8+ T cells | Skin cancer | Similar results from immunization as that of dendritic cell vaccination in cancer treatment | [106] |
| 2. | Polyethylene glycol (PEG) hydrogels | Human cell lines produced from metastatic melanoma (A375) and the radial growth phase (WM35) | Skin cancer | PLX4032 (vemurafenib)’s cytotoxicity decreased on more flexible substrates via metastatic A375 cells, which resulted in decreased proliferation rather than an increase in death | [107] |
| 3. | PEG-peptide hydrogels | Radial growth phase human melanoma cells (WM35) and metastatic cells (A375) | Skin cancer | Drug sensitivity in cells was reduced by 3D spherical models compared to 2D ones | [108] |
| 4. | Lanthanum-doped chitosan (La-CS) hydrogels | Mouse melanoma cells (B-16) and skin fibroblast cells (L929) | Skin cancer | B-16 melanoma cell proliferation is anticipated, while L929 skin fibroblast cell toxicity is decreasing | [109] |
| 5. | Sericin/dextran composite-hydrogels | Human liver cells (HL7702) and mouse myoblast cells (C2C12) | Skin cancer | Substantial conquest of cancer growth via hydrogel loaded with doxorubicin | [110] |
| 6. | Paclitaxel-encapsulated cell-penetrating-peptide-modified transfer-somes-embedded hydrogel (PTX-CTs/Gel) | Mouse melanoma cells (B16F10) | Skin cancer | A decrease in cancerous cell proliferation combined with systemic chemo through Taxol® | [111] |